PATENT CLAIM ANALYSIS

Application Number: 16040012
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "294000"]

Abstract:
Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.

Claim (Index 11):
The method of  claim 10 , further comprising:\n (i) determining after about one week of treatment the degree of control of abnormal involuntary movement achieved with the initial daily amount of deutetrabenazine and the tolerability of the initial daily amount; and (ii) increasing the daily amount of the deutetrabenazine by at least about 6 mg/day to a first subsequent daily amount if abnormal involuntary movement is not reduced and the initial daily amount is tolerated; (iii) optionally, repeating steps i) and ii) after one week until abnormal involuntary movement is reduced and the first subsequent daily amount is tolerated; and (iv) decreasing the daily amount by at least about 6 mg/day to a second subsequent daily amount if any amount is not tolerated.

Metadata:
- Claim Count in Document: 71.0
- Percentile: 95.0
- Lexical Diversity: 1.16667
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14900028', '11355339', '12638227', '14307195', '11340802']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6995034849098992
- 35 USC 102 Novelty (BERT): 0.5307322007493065
- Combined Prediction Score: 0.68262635649384
- Mean Citation Score: 254.932838
- Max Citation Score: 300.44366
- Similarity Product: 163.03363427514316

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test